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OVER the past few decades the implementation of new immunosuppressive regimens has remarkably im-
proved the success of clin!cal transplantation. Immuno-
suppressive drugs that can inhibit both cell-mediated and 
humoral immune responses have an important role in 
controlling acute cellular rejection and chronic rejection. 
In this report we compare the inhibitory effects of four 
antiproliferative drugs: two purine synthesis inhibitors, 
mycophenolic acid (MPA)l and mizorbine (MZR),2 and 
two pyrimidine synthesis inhibitors, brequinar sodium 
(BQR)3 and N-phosphonacetyl-L-aspartic acid (PALA).4 
A variety of in vitro culture systems have been used to 
determine the potency of these drugs including T-cell 
activation via calcium (Ca)-dependent (A23187) and Ca-
independent (lnterleukin-2 [IL-2] and Phorbol myristic 
acetate [PMAD pathways. Transformed T and non-T cells 
were also used to test the effect of these antiproliferative 
drugs. 
MATERIALS AND METHODS 
Cells 
Peripheral blood lymphocytes were isolated by Ficoll-Hypaque 
gradient centrifugation of heparinized blood from healthy donors. 
Cells were resuspended in RPMI 1640 tissue culture medium 
(TCM) supplemented with 2S nmoUL Hepes buffer and 100 UlmL 
gentamicin and 5% normal human serum. 
Reagents 
FK 506 and cyclosporin A (CyA) (Sandoz, Basel, Switzerland) 
were dissolved in methanol (l mg/mL). The MPA (Sigma Chem-
ical Co, St Louis, Mo), and MZR were dissolved in ethanol and 
water, respectively, before use. The BQR and PALA were 
suspended in distilled water. 
Proliferative Responses of Lymphocytes 
Mononuclear cells were cultured in TCM at lOS cells/well in the 
presence of A23187 (ll-'8lmL) or PMA (0.1 ~miF in a volume of 
200 ~ for 3 days. Interleukin-2-induced proliferation was mea-
sured by culturing alloreactive T cells (2 x lit cells/well) in the 
presence of 30 IU of IL-2 for 3 days. 
Mixed lymphocyte reaction (MLR assays) were established 
with equal numbers of responder cells (5 x lit cells/well) and 
irradiated stimulator cells in TCM and incubated for 6 days. For 
the secondary proliferative response (PLTI, alloreactive T cells 
(2 x I <t cells/well) were incubated with irradiated stimulator cells 
for 3 days. 
Proliferative Responses of Various Cell Lines 
T-Iymphoma cell lines (DND4I, Peer), Epstein-Barr (EB) virus-
transformed lymphoblastoid cell lines, a B-Iymphoma cell line 
(RPMI-1788), an erythroleukemia cell line (KS62), and a promy-
elocytic cell line (HL-60) were maintained in 10% TCM with fetal 
calf serum. Proliferation was measured after 72 hours of incuba-
tion by 3H-thymidine incorporation. 
Drug Inhibition Assays 
The inhibitory effects of various drugs alone or in combination were 
measured at different concentrations. The percent inhibition was 
calculated as follows: % inhibition = (I - {cpm with drugicpm 
without}) x 100. 
RESULTS 
Table 1 summarizes the drug dose required to obtain 50% 
inhibition (IC50) for five immunosuppressive drugs. Both 
BQR and MPA showed similar IC50 (80 to 100 nmoUL) in 
both Ca-dependent and Ca-independent T-cell prolifera-
tion. The IC50 for MZR was about 100-fold higher than that 
observed for MPA or BQR. FK 506 and CyA exhibited 
significant inhibition of Ca-ionophore stimulation (IC50 
0.18 nmoUL and 23 nmoUL, respectively) but had no effect 
on IL-2 and PMA stimulation. These data suggest that 
BQR and MPA have similar in vitro potency for suppress-
ing both Ca-dependent and Ca-independent T-cell activa-
tion pathways. The PALA, which was also tested in 
Table 1. Inhibitory Effects of Immunosuppressive Drugs on 
T-cell Proliferation 
IC 50 nmollL' 
FK506 CyA SOR MPA MZR 
Mitogen 
A23187 0.18 23 88 81 NT 
IL-2 No Inhibition 75 119 7,637 
PMA No Inhibition 100 81 14,861 
Allostimulation 
Primary (MLR) 0.1 10 50 103 14,706 
Secondary (PLT) 0.17 29 18 163 28,761 
'Concentration of drugs required to obtain 50% Inhibition 1C5O. 
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various T-cell activation assays, had minimal inhibitory 
effect even at a high dose of 10 /-Lg/mL (data not shown). 
All five immunosuppressive drugs inhibited the primary 
MLR and the secondary PL T proliferation of alloreactive 
T cells. In these assays BQR was two- to fourfold more 
potent than MPA whereas MZR and PALA were about 
1<Y- and 104-fold, respectively, less active than BQR 
(Table O. Combinations of low doses of BQR, MPA, or 
MZR with FK 506 showed, at best, an additive effect in the 
suppression of PLT responses (data not shown). 
The MPA uniformly inhibited all cell lines tested at drug 
concentrations of 90 to 365 nmoVL, whereas BQR ap-
peared to have a more restricted pattern of inhibition. 
Proliferation of EB virus B-celliines and HL-60 cells were 
inhibited by BQR at a concentration of 250 nmoUL, 
whereas T-Iymphoma cell lines were resistant even at high 
doses of BQR (100 !J.g/mL). All cell lines tested were 
resistant to the inhibitory effects of PALA. 
DISCUSSION 
This study demonstrates that BQR, MPA, and MZR 
inhibit the proliferative responses of normal T cells to 
mitogenic and allogeneic stimulation, whereas P ALA has a 
minimal effect. The proliferative responses of T cells 
induced by T-cell receptor, IL-2, and protein kinase C are 
equally affected by BQR, MPA, and MZR, since these 
drugs block DNA synthesis. l -4 In contrast, FK 506 and 
CyA are more efficient in blocking signal transduction via 
T-cell receptors by inhibiting the transcription of early 
activation genes.5 •7 
T and B cells lack the salvage pathway found in other 
types of cells and depend solely on the de novo pathway of 
purine and pyrimidine synthesis.8,9 Although both BQR 
and P ALA efficiently inhibit the de novo pyrimidine syn-
thesis, T cells are 103 to lW times more sensitive to the 
immunosuppressive effects of BQR than PALA. The 
BQR, an anticancer drug, exerts its antiproliferative activ-
ity by noncompetitively inhibiting the activity of de hydro-
orotate dehydrogenase, the fourth enzyme in the de novo 
pyrimidine biosynthetic pathway. 3,9 The P ALA inhibits 
DNA synthesis by blocking the second enzyme aspartate 
transcarbamylase in the de novo pyrimidine pathway.4 
Growth inhibition of P ALA can be easily reversed by 
carbamyl-L-asparate, whereas BQR inhibitory activity is 
not affected by the addition of dihydroorotic acid. 10.11 The 
BQR inhibits the. growth of a broad spectrum of murine 
and human solid tumors, whereas P ALA is effective 
against a limited number of solid tumors. 12 Consistent with 
these findings are our observations that BQR blocks the 
proliferative responses of many lymphoid and nonlym-
phoid cell lines, while PALA, even at 100 !J.g/mL, had only 
a minimal inhibitory effect on nonlymphoid cell lines. 
Other antiproliferative drugs such as MPA and MZR 
have also been shown to have both antitumor and immu-
nosuppressive activities, 13.14 The MPA, an antibiotic, in-
hibits reversibly and noncompetitively only inosine mono-
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phosphate dehydrogenase (IMPDH), an enzyme in the de 
novo purine biosynthetic pathway. Mizorbine, which is an 
imidazole nucleoside, also inhibits IMPDH but is 102_ to 
103-fold less active in blocking T-cell proliferation than 
MPA or BQR, respectively. 
All anti-DNA synthesis drugs tested act at a late stage of 
the cell activation pathway by blocking the movement of 
cells from Gl to S, whereas FK 506 and CyA act at an 
early stage of T-cell activation by inhibiting cell division 
cycle at GO/G 1 interface. Since T cells and B cells depend 
on de novo nucleotide synthesis, both humoral responses 
mediated primarily by B cells and cellular immune re-
sponses governed by T cells could be significantly im-
paired in the presence of purine and pyrimidine inhibi-
tors. 15,16 The MPA and its acid derivative RS 61443 have 
shown promising results in preventing acute cellular rejec-
tion in an experimental canine renal allograft model and in 
suppressing chronic rejection associated with vasculitis in 
a rat heart allograft model. I7 Also BQR is effective in 
suppressing the development of contact sensitivity and 
adjuvant arthritis in rodent models and preventing kidney, 
heart, and liver allograft rejection in rats. 16 
Although no synergism between BQR, MPA, or MZR 
with FK 506 was observed in inhibition of allogeneic T cell 
proliferation, an additive effect was seen. 18 Thus, the 
antiproliferative drugs may offer an alternative regimen 
when used in combination with other immunosuppressive 
drugs in treatment of acute and chronic cellular rejection. 
However, the most important benefit from the introduc-
tion of the experimental antimetabolite drugs or the estab-
lished anti-DNA synthesis drug cyclophosphamide, is the 
ability to break down the antibody barrier to xenotrans-
plantation. 19 Murase et al l9 have recently shown that the 
combination of FK 506 with either one of the anti-DNA 
synthesis inhibitors significantly prolongs the survival of 
hamster to rat heart or liver xenotransplantation by sup-
pressing the anti-hamster antibody response. 
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